{
  "event_id": "2744ae8c1c4f",
  "ticker": "INCY",
  "company_name": "Incyte Corporation",
  "drug_name": "Ruxolitinib Cream Opzelura",
  "pdufa_date": "2025-09-19",
  "approval_type": {
    "status": "found",
    "value": "nda",
    "source": "websearch:TRuE-AD/TRuE-V Phase 3",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.392378",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "Mild-moderate atopic dermatitis (2+); Nonsegmental vitiligo (12+)",
    "source": "websearch:TRuE-AD/TRuE-V Phase 3",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.392380",
    "error": null
  },
  "generic_name": {
    "status": "found",
    "value": "ruxolitinib",
    "source": "websearch_fda",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:05:16.351049",
    "error": null
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Dermatology",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:58.812996",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Phase 3",
    "source": "websearch_clinical",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:05:16.351049",
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:TRuE-AD/TRuE-V Phase 3",
    "confidence": 0.85,
    "evidence": [
      "TRuE-AD/TRuE-V Phase 3"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.392364",
    "error": null
  },
  "p_value": {
    "status": "found",
    "value": "<0.001",
    "source": "websearch:TRuE-AD/TRuE-V Phase 3",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.392373",
    "error": null
  },
  "p_value_numeric": 0.001,
  "effect_size": {
    "status": "found",
    "value": "AD: IGA-TS 53.8% vs 7.6% vehicle; Vitiligo: F-VASI75 30% at Week 24, 50% at Week 52",
    "source": "websearch:TRuE-AD/TRuE-V Phase 3",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.392375",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "default_for_approved",
    "confidence": 0.9,
    "tier": 1,
    "note": "No blocking safety signals at approval"
  },
  "phase3_study_names": [
    "A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis",
    "Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis"
  ],
  "nct_ids": [
    "NCT03745638",
    "NCT03745651"
  ],
  "enrollment": {
    "count": 631,
    "type": "ACTUAL",
    "nct_id": "NCT03745638",
    "source": "clinicaltrials.gov",
    "fetched_at": "2026-01-10T17:27:45.083470"
  },
  "has_prior_crl": {
    "status": "found",
    "value": false,
    "source": "derived_from_first_submission",
    "confidence": 0.95,
    "tier": 2
  },
  "prior_crl_reason": null,
  "is_resubmission": {
    "status": "found",
    "value": 0,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "result": "approved",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:17:48.007034",
  "enriched_at": "2026-01-11T19:05:32.987990",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "eb0d31426070",
  "fda_designations": {
    "breakthrough_therapy": false,
    "fast_track": true,
    "priority_review": true,
    "orphan_drug": false,
    "accelerated_approval": false
  },
  "mechanism_of_action": "JAK1/2 inhibitor",
  "adcom_info": {
    "scheduled": false,
    "held": false,
    "outcome": null,
    "vote": null
  },
  "days_to_pdufa": -113,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:40.030337",
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:39:31.293570"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:39:31.293578"
  },
  "breakthrough_therapy": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:05:13.820823",
    "search_status": "CONFIRMED_NONE"
  },
  "orphan_drug": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:05:18.584129",
    "search_status": "CONFIRMED_NONE"
  },
  "priority_review": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:05:23.455545",
    "search_status": "CONFIRMED_NONE"
  },
  "fast_track": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:05:28.227086",
    "search_status": "CONFIRMED_NONE"
  },
  "accelerated_approval": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:05:32.987973",
    "search_status": "CONFIRMED_NONE"
  }
}